add-on Low Dose Memantine in Middle-to-old Aged Bipolar II Disorder Patients
Status:
Recruiting
Trial end date:
2022-07-31
Target enrollment:
Participant gender:
Summary
The investigators hypothesized that add-on memantine (MM) 5 mg/day may reduce chronic
inflammation, and subsequently improve neuro-progression process and cognitive function in
middle-to-old aged bipolar II disorder (BP-II) patients. In current proposal, the
investigators will conduct a randomized double-blind placebo-controlled study. The
investigators will recruit 100-120 patients with BP-II who are older than 40 years old in
three years, and allocate them to add-on MM or placebo plus standard valproic acid treatment
in a 1: 1 ratio. The investigators will follow up the participants for 12 weeks and measure
the severity of mood symptoms, neuropsychological tests and inflammatory markers to evaluate
the therapeutic effects of add-on MM.